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Abstract
Background: Our objective was to test a brief, symptom index for advanced renal cell carcinoma,
a disease affecting over 38,000 Americans each year and often diagnosed in late stages.
Methods:  We conducted secondary data analyses on patient-reported outcomes of 209
metastatic renal cell carcinoma patients participating in a Phase III clinical trial. Patient-reported
outcomes, obtained from the FACT-Biological Response Modifier (FACT-BRM) scale, were
available at baseline, 2, and 8 weeks. We analyzed data from eight FACT-BRM items previously
identified by clinical experts to represent the most important symptoms of advanced renal cell
carcinoma. Items comprising this index assess nausea, pain, appetite, perceived sickness, fatigue and
weakness, with higher scores indicating fewer symptoms. We determined reliability and validity of
the index and estimated a minimally important difference.
Results: The index had excellent internal reliability at all three time points (alphas ≥ 0.83). Baseline
scores were able to discriminate patients across Karnofsky performance status, number of
metastatic sites, and risk group categories (ps < .01). Mean index scores declined over time likely
indicative of the toxic nature of the administered treatments. Distribution- and anchor-based
methods converged on a minimally important difference estimate of 2 to 3 points.
Conclusion: The 8-item index of patient-reported symptoms of renal cell carcinoma appears to
be a psychometrically sound measure. It is a brief, reliable, and valid measure that can easily be
adapted for use in clinical trials and observational studies.
Background
Renal cell carcinoma (RCC) is estimated to affect over
38,000 Americans annually and account for over 12,000
deaths [1]. It is often diagnosed in advanced stages, with
varied sites of metastases. Due to uniform resistance to
most cytotoxic chemotherapy agents [2], patients with
metastatic RCC typically have very poor prognoses.
Though not curative, biological response modifiers such
as interleukin-2 and interferon-alfa have proven effective
at delaying tumor growth and disease progression. How-
ever, these treatments can result in severe and sometimes
dose-limiting toxicities such as fever, chills, nausea, vom-
iting, hypotension, and fatigue [3].
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Recently, less-toxic targeted therapies have shown anti-
tumor activity in clinical trials of metastatic RCC. Among
the most promising agents are bevacizumab (Avastin),
sorafenib (Nexavar) and sunitinib (Sutent). Bevacizumab,
approved for the treatment of metastatic colorectal cancer
in 2004, has also shown clinical activity in metastatic RCC
[4]. Sorafenib, an oral multi-kinase inhibitor, has demon-
strated anti-tumor activity in several solid tumors includ-
ing RCC [5,6]. A recent Phase II trial demonstrating the
efficacy of second-line sunitinib – a multi-targeted, tyro-
sine kinase inhibitor – has led to the rapid approval of this
drug for the treatment of metastatic RCC [7]. Though bet-
ter tolerated than immunotherapy, such targeted thera-
pies have been associated with a host of toxicities
including fatigue, diarrhea, nausea, dyspepsia, hyperten-
sion, proteinuria, rash, and malaise. Hence, regardless of
treatment type, the clinical picture of advanced RCC fea-
tures an array of symptoms and complications.
Measurement of symptoms and complications has often
been done using common toxicity criteria, global meas-
ures of performance status, and/or formal quality of life
assessment. Though the latter has proven highly effective
at measuring subjective patient status in many functional
areas, regulatory agencies and clinicians sometimes prefer
briefer, symptom-focused instruments in clinical trials. To
meet the need for brief and focused assessment of symp-
toms and complications associated with advanced RCC
and its treatment, we used clinical experts to identify an 8-
item index of questions from an available health-related
quality of life (HRQL) questionnaire. Here we attempt to
validate this index using data from a Phase III clinical trial.
A secondary objective was to determine a minimally
important score difference for the index.
Methods
Development of the index
The index of RCC symptoms and complications was
developed in consultation with four medical oncologists
with substantial expertise in the treatment of metastatic
RCC. All were employed at large academic medical centers
at the time of this study. These experts were shown a pool
of items from a previously validated tool used to assess
HRQL in patients treated with biological response modi-
fiers – the Functional Assessment of Cancer Therapy –
BRM (FACT-BRM) [8]. The FACT-BRM consists of 40
items, divided into 5 subscales: physical, functional,
social, and emotional well-being and BRM-specific con-
cerns. The first four subscales form the FACT-General, a
measure of cancer-specific quality of life. The BRM con-
cerns subscale consists of physical and mental concerns
and issues relevant to patients receiving immunotherapies
like interleukin-2 and interferon-alfa. Experts were asked
to nominate a brief list of items from the FACT-BRM rep-
resenting the clinical issues of greatest relevance in the
advanced RCC setting. This could include symptoms asso-
ciated with tumor burden as well as side effects of cur-
rently available or newly emerging treatment regimens.
These experts agreed on the inclusion of the following
eight items for the index:
- I have a lack of energy
- I have nausea
- I have pain
- I feel sick
- I am forced to spend time in bed
- I get tired easily
- I feel weak all over
- I have a good appetite
We maintained the 5-point ordinal rating scale of the orig-
inal FACT-BRM, with responses ranging from 0 – 'not at
all' to 4 – 'very much'. An aggregated symptom index score
is created by first reverse-coding the negatively-worded
items (all items except "I have a good appetite") then
summing the responses to all 8 items so that a higher
score indicates fewer symptoms and better well-being.
Hence, the worst possible score is 0 and the best possible
score is 32.
Validation of the index
Data source
We conducted secondary data analyses on 209 advanced
RCC patients with available HRQL data (70% male; mean
age = 58.1 years) who were entered on a multi-center ran-
domized Phase III trial comparing interferon with or with-
out 13-cis-retinoic acid. Participating centers included
Memorial Sloan-Kettering Cancer Center (54 patients)
and member institutions of the Eastern Cooperative
Oncology Group (155 patients). The trial was approved
by the institutional review boards of each participating
center. All patients provided informed consent. For more
complete trial details see Motzer and colleagues (2000)
[9]. Patients in the trial were required to have a pretreat-
ment Karnofsky Performance Status greater than 60% and
an estimated life expectancy of more than 3 months. Over
half (53%) of patients in this analysis had a prior nephrec-
tomy. The full 40-item FACT-BRM scale was used in the
trial. For validation purposes, we extracted and scored the
eight FACT-BRM items constituting the proposed symp-
tom index. Assessments were conducted at baseline (prior
to treatment) and at 2, 8, 17, 34, and 52 weeks after the
initiation of therapy. Since completion rates fall wellHealth and Quality of Life Outcomes 2006, 4:68 http://www.hqlo.com/content/4/1/68
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below 50% by 17 weeks, we considered only the baseline,
2 week, and 8 week data. Data were aggregated across
treatment.
Data analyses
Internal reliability was determined by computing Cron-
bach's alpha coefficients and inter-item correlations at
each of the three time points. Concurrent validity was
determined by comparing baseline index scores across
various clinical parameters using one-way analyses of var-
iance (ANOVA) and independent sample t-test. Index
scores were compared across Karnofsky performance sta-
tus, number of identified metastatic sites, and prognostic
risk group. These parameters were either directly available
from clinical report forms or, in the case of risk group,
determined from a composite of pretreatment features
available on the forms. We determined responsiveness to
change over time by comparing baseline to follow-up
index scores using repeated-measures ANOVA. Least sig-
nificant difference post-hoc tests were used to specify pair-
wise differences for any significant omnibus F-test.
Finally, we computed an estimate for a minimally impor-
tant difference (MID) for the index using both distribu-
tion- and anchor-based analyses [10]. The MID is the
smallest difference in score likely to be clinically meaning-
ful to patients and clinicians. Distribution-based meas-
ures included 1/3 and 1/2 of the standard deviation and
one standard error of measurement (SEM). Anchor-based
analyses compare index score differences between clini-
cally distinct groups. Magnitude differences falling within
an effect size range of 0.20 to 0.60 will be those consid-
ered minimally important. The effect size is computed as
a mean difference between clinically distinct groups
divided by the pooled within-group standard deviation.
Results
Reliability
Internal consistency reliability for the index was quite
good in this sample of patients. Cronbach's alpha coeffi-
cients were 0.83, 0.86, and 0.86 at baseline, 2 weeks, and
8 weeks, respectively. Inter-item correlations demonstrate
that the symptoms and complications represented in the
items appear to co-vary with one another. After reverse-
coding of negatively-worded items, the number of inter-
item correlations reaching at least rho = 0.25 was 23 of 28
(82%) at baseline, 27 of 28 (96%) at 2 weeks, and 26 of
28 (93%) at 8 weeks. The number of inter-item correla-
tions reaching at least rho = 0.50 was 7 of 28 (25%) at
baseline, 10 of 28 (36%) at 2 weeks, and 11 of 28 (39%)
at 8 weeks.
Concurrent validity
Baseline index scores were compared across clinically dis-
tinct groups to determine concurrent validity. As shown in
Table 1, these scores differentiated groups based on
Karnofsky performance status (KPS), number of estab-
lished metastatic sites and prognostic risk category.
Patients with higher (better) performance status had
higher index scores at baseline than did patients with
lower (worse) performance status. In particular, patients
with a KPS rating of 80 or 90 had higher mean index
scores than did patients with a KPS rating of 70 (ps < .01).
Table 1: Mean Index Scores By Baseline Clinical Parameters
Karnofsky rating2
90 (n = 113) 80 (n = 45) 70 (n = 30) F (post-hoc)4 Adjacent category mean 
differences & effect sizes
Index score1 24.76 (sd = 5.62) 22.89 (sd = 6.84) 18.34 (sd = 4.65) F(2, 185) = 14.67***
80,90 > 70
1.87 (0.30), 4.55 (0.73)
No. of metastatic sites
0 or 1 site (n = 72) 2 or more sites (n = 
116)
t Mean difference & effect size
Index score 24.81 (sd = 5.57) 22.34 (sd = 6.42) t(186) = 2.69** 2.47 (0.40)
Risk group3
Favorable (F) (n = 47) Intermediate (I) (n = 95) Poor (P) (n = 41) F (post-hoc)4 Adjacent category mean 
differences & effect sizes
Index score 26.96 (sd = 3.82) 23.35 (sd = 6.20) 19.47 (sd = 6.06) F(2, 180) = 19.18***
F > I > P
3.61 (0.58), 3.88 (0.63)
Note. 1Higher score, indicates fewer symptoms and better well-being. 290 = Able to carry on normal activity, minor signs or symptoms of disease. 
80 = Normal activity with effort, some signs or symptoms of disease. 70 = Cares for self, unable to carry on normal activity or do active work. 
3Based on pretreatment features associated with shorter survival. These include: low Karnofsky rating (< 80%), high lactate dehydrogenase level (≥ 
1.5 times upper limit of normal), low hemoglobin level (≤ lower limit of normal), high corrected serum calcium (≥ 10 mg/dL), and absence of 
nephrectomy. Favorable risk = 0 risk factors present. Intermediate risk = 1–2 risk factors present. Poor risk = 3 or more risk factors present. 
4Pairwise post-hoc comparisons made using least significant difference test.
**p < .01 ***p < .001Health and Quality of Life Outcomes 2006, 4:68 http://www.hqlo.com/content/4/1/68
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Though patients with a KPS rating of 90 had a higher
mean baseline index score than patients with a KPS rating
of 80, this difference was not statistically significant (p =
.07). As shown in Table 1, patients with 0 or 1 metastatic
site were compared to patients with multiple metastatic
sites. Patients with 0 or 1 metastatic site prior to study
treatment had significantly higher baseline index scores
than patients with multiple metastatic sites prior to treat-
ment (p < .01).
A previously developed prognostic factor model was used
to define and categorize patients into risk groups. The
model, derived from an analysis of 670 advanced RCC
patients treated in clinical trials at the Memorial Sloan-
Kettering Cancer Center between 1975 and 1996, classi-
fies patients into risk groups based on pretreatment clini-
cal features associated with shorter survival time [11].
These include: low performance status (KPS < 80), high
lactate dehydrogenase (≥ 1.5 × 200 U/L – the upper limit
of normal), low hemoglobin level (≤ the lower limit of
normal: normal Hgbmale = 13 g/dL and normal Hgbfemale =
11.5 g/dL), high corrected serum calcium (≥ 10 mg/dL),
and absence of nephrectomy. Patients with 0 factors
present are classified as favorable risk, those with 1 or 2
factors present are classified as intermediate risk, and
those with 3 or more factors present are classified as poor
risk. Baseline index scores were compared across these
three risk groups (see Table 1). Patients with a favorable
risk had significantly higher mean baseline index scores
than did patients with either an intermediate or a poor
risk (ps < .001). Patients with an intermediate risk had a
higher mean baseline index score than patients with a
poor risk (p < .001).
Responsiveness to change
To determine whether items from the index are reflective
of symptoms and complications that will change over the
course of treatment for advanced RCC, we plotted mean
scores of the eight individual items (see Figure 1). Consist-
ent with the clinical profile of patients on interferon,
many complications emerge upon the introduction of
therapy. Mean levels of fatigue (lack of energy, getting
tired, and feeling weak) increased from baseline to 2
weeks and did not fall at 8 weeks. Nausea, spending time
in bed, and feeling sick – all low at baseline – rose moder-
ately at 2 weeks and did not fall substantially at 8 weeks.
Good appetite, high at baseline, declined some from base-
line to 2 and 8 weeks. Pain, an important clinical indica-
tor in metastatic disease, rose slightly over time. This
pattern of fluctuation in the individual items justifies
aggregation into a single index. A repeated-measures
ANOVA was conducted on index scores across the three
Index item means at baseline, 2 weeks, and 8 weeks (complete cases)1 Figure 1
Index item means at baseline, 2 weeks, and 8 weeks (complete cases)1. 1Note. Number of complete cases fluctuates 
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time points to determine responsiveness to change (com-
plete cases only, n = 92). Index scores did change over
time; F (2, 182) = 39.40, p < .001. Consistent with the
changes observed in the individual items, the total index
score dropped significantly from baseline (mean = 24.66,
sd = 5.36) to 2 weeks (mean = 19.62, sd = 6.71) (p < .001)
and remained significantly lower than baseline at 8 weeks
(mean = 18.74, sd = 7.17) (p < .001).
Minimally important difference
A minimally important difference (MID) was estimated
by combining multiple distribution- and anchor-based
analyses. The standard deviations of baseline, 2 week, and
8 week index scores were divided by 3 and 2 to determine
1/3 and 1/2 standard deviation (SD) estimates for an
MID. Estimates based on 1/3 SD ranged from 2.07 to
2.38; estimates based on 1/2 SD ranged from 3.11 to 3.58.
The SD-based criteria were supplemented by a second dis-
tribution-based parameter, the standard error of measure-
ment (SEM). The SEM was computed at each of the three
time points as, SD × (1 - reliability)1/2. SEMs for the three
time points ranged from 2.56 to 2.68. Using these three
distribution-based parameters, it appears that the MID for
this index falls within the range of 2 to 3 points.
Anchor-based analyses were used to refine or confirm the
MID estimate. Score differences between distinct groups
were computed along with corresponding effect sizes. The
baseline cross-sectional comparisons in the table were
used to define these groups. Clinically distinct groups
were defined as adjacent response categories for each of
the clinical parameters used. For example, in analyses of
Karnofsky performance status, patients with a KPS rating
of 90 were compared to patients with a KPS rating of 80
and patients with a KPS rating of 80 were compared to
patients with a KPS rating of 70. Comparing index scores
of patients with a KPS rating of 90 to those with a KPS rat-
ing of 70 was not used since this contrast exceeds a mini-
mal level of clinical distinction. These adjacent category
differences in index scores as well as their corresponding
effect sizes are shown in the last column of Table 1. Only
the magnitude differences that fall within an effect size
range of 0.20 to 0.60 were considered minimally impor-
tant. This corresponds to a 'small' to 'medium' effect [12],
which we have found to be a reasonable approximation of
an MID on FACT measures [10]. Three of the five minimal
group differences fell within this effect size range. These
three mean differences ranged from 1.87 to 3.61. Com-
bining these results with the results of the distribution-
based analyses, we conclude that the MID on the index
most likely falls within the range of 2 to 3 points.
Discussion and conclusion
Our newly developed index for assessing symptoms and
complications associated with advanced RCC performed
well psychometrically. The index had excellent internal
reliability across all three time points. The moderate to
high inter-item correlations indicate that this set of items
represents a constellation of coexisting symptoms. This is
further borne out by the longitudinal changes in item
scores. All symptoms tended to worsen from pretreatment
to the on-therapy follow-up points. Hence, aggregating
these eight items into a common index score appears jus-
tified and is in line with recent FDA guidance on the con-
struction and use of patient-reported outcome measures
(PROs) [13]. Supportive of its validity, baseline scores on
the index differentiated clinical patient groupings based
on Karnofsky performance ratings, number of metastatic
sites, and prognostic risk. A combination of distribution
and anchor-based analyses identified an MID estimate of
2 to 3 points.
There are a few noteworthy limitations to this study. First,
the development of the index relied entirely on physician
input. Results could have been different had input from
patients also been sought. Future efforts to improve and
refine the index would benefit from patient query. Sec-
ond, some of the newer targeted, anti-cancer agents may
result in toxicities (i.e., rash and diarrhea) that are not
directly addressed in the current index. To address these
issues, it may be possible to augment the index with a few
items drawn from other established measures including
those within the FACT measurement system (see review
by Eton, Yost & Cella) [14]. However, any substantial
modification to the existing index will require re-valida-
tion. Third, some of the group sample sizes in the baseline
index comparisons are modest (N's < 50). This may limit
the generalizability of the validation and MID results.
Finally, we used only cross-sectional (baseline) data in the
anchor-based analyses for determining the MID. Confir-
mation of the MID using longitudinal methods is war-
ranted. Furthermore, replication of the MID analyses in
other RCC samples, especially in patients receiving thera-
pies different from those studied in this report, would
enhance the generalizability of the estimate.
Based on these results this index would appear to be a rea-
sonable choice as an endpoint in clinical studies of
advanced RCC. It is a brief, clinically-derived measure
with excellent psychometric properties. Many current and
planned Phase II and III clinical trials in the RCC setting
include therapeutic combinations in which an array of
complications may emerge [6,15]. Some of these trials
combine standard immunotherapy with newer targeted
agents (e.g., bevacizumab, sorafenib, sunitinib). Others
are directly comparing the clinical benefit of newer tar-
geted therapies versus standard immunotherapy. Given
this picture, symptom assessment will need to be broad
enough to capture toxicities associated with both immuno-
and targeted therapy as well as symptoms of metastaticPublish with BioMed Central    and   every 
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disease. The index reported herein provides the clinical
investigator with a good foundation for an assessment of
PRO endpoints in metastatic RCC.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
DE participated in the design of the study, performed the
statistical analysis and interpretation of data, and drafted
the manuscript. DC participated in the design and con-
ception of the study and helped revise the manuscript for
important intellectual content. JB assisted with the acqui-
sition and interpretation of data, and helped revise the
manuscript for important intellectual content. RM
assisted with data acquisition and helped revise the man-
uscript for important intellectual content. All authors
have read and approved the final manuscript.
Acknowledgements
This study was supported in part by a grant from the National Cancer Insti-
tute (CA 05826) and by Genentech, Inc., South San Francisco, CA. We 
thank Joel Wallace and Anita Chawla at Genentech, Inc. for conceptual 
assistance and technical support.
References
1. American Cancer Society: Cancer Facts & Figures  2006.  Atlanta,
GA, American Cancer Society; 2006. 
2. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma.
J Urol 2000, 163:408-417.
3. Borden EC, Parkinson D: A perspective on the clinical effective-
ness and tolerance of interferon-alpha.  Semin Oncol 1998,
25:3-8.
4. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topa-
lian SL, Steinberg SM, Chen SX, Rosenberg SA: A randomized trial
of bevacizumab, an anti-vascular endothelial growth factor
antibody, for metastatic renal cancer.  N Engl J Med 2003,
349:427-434.
5. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H,
Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activ-
ity of BAY 43-9006 in metastatic renal cell carcinoma and
other advanced refractory solid tumors in a phase II rand-
omized discontinuation trial (RDT) [abstract 4501]: ; New
Orleans, LA.  Volume 22. ASCO; 2004:381s. 
6. Stadler WM: Targeted agents for the treatment of advanced
renal cell carcinoma.  Cancer 2005, 104:2323-2333.
7. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin
RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL,
Theuer CP, George DJ, Rini BI: Activity of SU11248, a multi-
targeted inhibitor of vascular endothelial growth factor
receptor and platelet-derived growth factor receptor, in
patients with metastatic renal cell carcinoma.  J Clin Oncol
2006, 24:16-24.
8. Bacik J, Mazumdar M, Fairclough DL, Murphy BA, Mariani T, Motzer
RJ, Cella D: The Functional Assessment of Cancer Therapy-
BRM (FACT-BRM): A new tool for the assessment of quality
of life in patients treated with biologic response modifiers.
Qual Life Res 2004, 13:137-154.
9. Motzer RJ, Murphy BA, Bacik J, Schwartz LH, Nanus DM, Mariani T,
Loehrer P, Wilding G, Fairclough DL, Cella D, Mazumdar M: Phase
III trial of interferon alfa-2a with or without 13-cis-retinoic
acid for patients with advanced renal cell carcinoma.  J Clin
Oncol 2000, 18:2972-2980.
10. Yost KJ, Eton DT: Combining distribution- and anchor-based
approaches to determine minimally important differences:
The FACIT experience.  Evaluation & the Health Professions 2005,
28:172-191.
11. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J:
Survival and prognostic significance of 670 patients with
advanced renal cell carcinoma.  J Clin Oncol 1999, 17:2530-2540.
12. Cohen J: Statistical Power Analysis for the Behavioral Sci-
ences.  2nd edition. Hillsdale, NJ, Erlbaum; 1988. 
13. Center for Drug Evaluation and Research: Guidance for Industry
Patient-Reported Outcome Measures: Use in Medical Prod-
uct Development to Support Labeling Claims.  Rockville, MD,
US Food and Drug Administration; 2006:1-32. 
14. Eton DT, Yost KJ, Cella D: Future trends in patient-reported
outcomes assessment for patients with advanced-stage lung
cancer receiving targeted therapy.  Clin Lung Cancer  in press.
15. Rini BI, Sosman JA, Motzer RJ: Therapy targeted at vascular
endothelial growth factor in metastatic renal cell carcinoma:
Biology, clinical results and future development.  BJU Int 2005,
96:286-290.